Press releases

29/11/2016 18:15
|

Initiation of coverage by Edison Investment Research

16/11/2016 17:00
|

Publication of the second issue of Quantum Genomics' shareholder newsletter - November, 2016

13/10/2016 18:00
|

Quantum Genomics announces 2016 first-half financial results and first nine months business update

29/09/2016 17:45
|

Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension

22/09/2016 18:00
|

Quantum Genomics Announces Conference Call to Review Top-line Results from Phase IIa Study of QGC001 in Hypertension

12/09/2016 18:00
|

Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016

30/06/2016 18:00
|

Quantum Genomics Initiates Phase IIa trial for Heart Failure, the second strategic initiative for its BAPAI therapeutic platform

28/06/2016 18:00
|

Quantum Genomics extends its collaboration agreement with its partner in animal health

02/06/2016 18:00
|

Publication of the first issue of Quantum Genomics' shareholder newsletter - June, 2016

31/05/2016 18:00
|

Quantum Genomics symposium at the European Meeting on Hypertension and Cardiovascular Protection

17/05/2016 18:00
|

Quantum Genomics granted two new U.S. patents covering lead product QGC001

26/04/2016 18:00
|

Regulatory authorisations received in France to begin Phase IIa multicentric European trial for heart failure

14/04/2016 18:00
|

2015 annual report : acceleration of clinical trials, secured financing and internationalisation in progress

24/03/2016 07:30
|

Quantum Genomics Raises EUR 8.6 Million in U.S. and Europe

17/03/2016 07:30
|

2016/03/17 - Quantum Genomics raises EUR 5.54m via private placement in the United States and launches a capital increase amounting to EUR 2.94m

03/02/2016 18:30
|

Quantum Genomics Expands U.S. Presence to Advance its Development Programs for Cardiovascular Diseases

20/01/2016 18:00
|

Enhancement of Quantum Genomics' intellectual property

05/01/2016 18:00
|

Patient enrolment 100% completed for Phase IIa trial for high blood pressure